Business

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio” or the "Company”), a biopharmaceutical company focused on…

The ATTR amyloidosis pipeline has expanded far beyond patisiran, with RNA interference, CRISPR gene editing, monoclonal antibodies, and next-generation stabilizers…

Transthyretin amyloidosis is driving intensive pharmaceutical IP activity across four mechanistically distinct modalities — RNAi silencing, small-molecule…

Anumana, a Massachusetts-based artificial intelligence (AI) company co-founded by nference and Mayo Clinic, has received U.S. Food and Drug Administration (FDA)…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI™…

The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge…

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a…

AbstractAmyloidosis comprises a heterogeneous group of disorders marked by the extracellular deposition of insoluble protein fibrils, known as amyloids, which can…

License agreement leverages UCB’s expertise in antibody drug discovery to support Refold Therapeutics' ambition of providing better treatments for patients…

TULSA, Okla. -Cardiac amyloidosis, once widely considered a fatal diagnosis, is now being detected earlier and treated with newly approved medications that doctors…